Literature DB >> 1851337

The role of platelet activating factor and its antagonists in shock, sepsis and multiple organ failure.

B O Anderson1, D D Bensard, A H Harken.   

Abstract

PAF has been implicated as a mediator of shock, sepsis and MOF. The results of experimental data demonstrate that PAF induces changes characteristic of endotoxemia and sepsis, including systemic hypotension and diffuse microvascular leakage. These effects are prevented by PAF antagonists. PAF induces many of the characteristic changes of MOF, including functional impairment in the lung, kidney, gastrointestinal tract and heart. PAF antagonists will inhibit these adverse effects. PAF antagonists are now being manufactured by a number of pharmaceutical companies studying the beneficial effects of PAF antagonists in human disease. Data from these studies promise valuable information with significant clinical relevance to the practicing surgeon.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1851337

Source DB:  PubMed          Journal:  Surg Gynecol Obstet        ISSN: 0039-6087


  22 in total

1.  Divergent roles of tumor necrosis factor and platelet-activating factor in endotoxin-induced release of monocyte chemoattractant protein 1 and macrophage inflammatory protein 1beta in chimpanzees.

Authors:  P E Dekkers; M Levi; S J van Deventer; T van der Poll
Journal:  Infect Immun       Date:  1999-10       Impact factor: 3.441

2.  The effects of PAF antagonist on intestinal mucosal microcirculation after burn in rats.

Authors:  Pei-Wu Yu; Guang Xia Xiao; Li-Xin Zhou; Zi-Qiang Wang
Journal:  World J Gastroenterol       Date:  2000-12       Impact factor: 5.742

3.  Pathogenetic effects of platelet activating factor on enterogenic endotoxemia after burn.

Authors:  Pei-Wu Yu; Guang-Xia Xiao; Wei-Ling Fu; Jian-Cheng Yuan; Li-Xin Zhou; Xiao-Jian Qin
Journal:  World J Gastroenterol       Date:  2000-06       Impact factor: 5.742

4.  A double-blind placebo-controlled study of an infusion of lexipafant (Platelet-activating factor receptor antagonist) in patients with severe sepsis.

Authors:  Y Suputtamongkol; S Intaranongpai; M D Smith; B Angus; W Chaowagul; C Permpikul; J A Simpson; A Leelarasamee; L Curtis; N J White
Journal:  Antimicrob Agents Chemother       Date:  2000-03       Impact factor: 5.191

Review 5.  The role of the microcirculation in multiple organ dysfunction syndrome (MODS): a review and perspective.

Authors:  C J Kirkpatrick; F Bittinger; C L Klein; S Hauptmann; B Klosterhalfen
Journal:  Virchows Arch       Date:  1996-02       Impact factor: 4.064

6.  Multidrug-resistance P-glycoprotein (MDR1) secretes platelet-activating factor.

Authors:  R J Raggers; I Vogels; G van Meer
Journal:  Biochem J       Date:  2001-08-01       Impact factor: 3.857

Review 7.  Clinical experience with platelet-activating factor antagonists. Past, present, and near future.

Authors:  P Guinot
Journal:  Clin Rev Allergy       Date:  1994

8.  Platelet-activating factor augments meningeal inflammation elicited by Haemophilus influenzae lipooligosaccharide in an animal model of meningitis.

Authors:  G C Townsend; W M Scheld
Journal:  Infect Immun       Date:  1994-09       Impact factor: 3.441

9.  Endothelin 1 and prostacyclin attenuate increases in hydraulic permeability caused by platelet-activating factor in rats.

Authors:  Elizabeth L Cureton; Terry J Chong; Rita O Kwan; Kristopher C Dozier; Javid Sadjadi; Brian Curran; Gregory P Victorino
Journal:  Shock       Date:  2010-06       Impact factor: 3.454

10.  Applying Ockham's razor to pancreatitis prognostication: a four-variable predictive model.

Authors:  Austin L Spitzer; Anthony M Barcia; Michael T Schell; Annabel Barber; James Norman; James Grendell; Hobart W Harris
Journal:  Ann Surg       Date:  2006-03       Impact factor: 12.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.